Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Increased levels of
S100A4
(p9Ka) confer metastatic ability on a normally non-metastatic epithelial cell line. To find out whether
S100A4
can induce metastasis in vivo, transgenic mice expressing high levels of
S100A4
, but which show no phenotypic effect, have been mated with MMTV-neu transgenic mice which succumb to stochastic mammary neoplasia related to expression of the MMTV-neu transgene. Resultant bitransgenic, multiparous, female progeny expressing both
S100A4
and Neu have a slightly earlier incidence of palpable mammary tumours than the MMTV-neu offspring and specifically exhibit macroscopic metastatic lesions in the lungs. The
S100A4
transgene is expressed in primary and secondary lesions of bitransgenic offspring and its expression is particularly associated with regions of invasion of primary lesions and
metastases
.
...
PMID:Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. 889 8
The purpose of this study was to evaluate the expression of the Ca(2+)-binding S100 proteins S100A1, S100A2, S100A3,
S100A4
, S100A6 and S100B in normal skin. These immunohistochemical staining patterns were compared with those in melanocytic lesions. Paraffin-embedded tissue of normal skin adjacent to 26 naevi, 39 primary cutaneous melanomas and 14 cutaneous melanoma
metastases
was incubated with polyclonal antibodies against the recombinant human S100 proteins (S100A1, S100A2, S100A3,
S100A4
, S100A6, S100B) using the alkaline phosphatase anti-alkaline phosphatase method. The S100A2 antibody stained the basal layer of the epidermis and hair follicles of normal skin. Four of 39 primary cutaneous melanomas were positive for S100A2, whereas none of the
metastases
or naevi showed any immunoreactivity. The S100A3 antibody only stained the inner root sheath cuticle of some hair follicles but no melanocytes or melanocytic lesions. Staining of
S100A4
was weak and thus omitted to further analysis. S100A6 faintly labelled keratinocytes. Langerhans' cells, melanocytes and sweat glands. S100A6 immunoreaction was found in two of seven junctional naevi, five of seven compound naevi, and all dermal and blue naevi. There was an intense cytoplasmatic reaction for S100A6 in all primary cutaneous melanomas and in nine of 14 (64%)
metastases
, S100B was positive in melanocytes and Langerhans' cells, all primaries as well as in the
metastases
, S100A1 protein was not detected on any of the tissue specimens examined. Whereas S100B and S100A6 antibodies are useful markers for malignant melanoma, expression of
S100A4
antibody is too low to be used for immunohistochemical staining. S100A1 and S100A3 antibodies are not expressed in melanocytic lesions and S100A2 is only found in selected tumours. The investigated S100 proteins, including S100B and S100A6, are also expressed in selected elements of normal skin. These findings are important for correct interpretation of staining patterns, when S100 antibodies are used as markers for melanoma or other tumours.
...
PMID:Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions. 927 23
Three members of the S100 gene family, S100A2,
S100A4
and S100A6, have been suggested to be associated with cancer development and metastasis. To study their involvement in the tumorigenesis of human melanoma, we examined the mRNA expression levels of the 3 genes in 45 melanoma
metastases
and in 20 benign nevi. Interestingly, whereas none of the
metastases
expressed S100A2 mRNA, and the expression level was low in 6 cell lines established from primary melanomas, all nevi showed moderate to high expression levels. Our results suggest that loss of S100A2 gene expression may be an early event in melanoma development. A significant correlation was found between the expression of S100A6 in melanoma
metastases
and both the survival time of the patients and the thickness of the corresponding primary tumors. For the
S100A4
gene, however, no relationship was found between gene expression and clinical parameters of melanoma malignancy. The observed differences in expression patterns of the 3 S100 genes suggest distinct roles of their products in melanoma tumorigenesis and/or metastasis, and the results encourage studies to evaluate the potential value of using S100A2 and S100A6 expression levels as markers in the clinical management of melanoma.
...
PMID:Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. 929 41
The metastatic spread of cancer is a little understood process, in part because it is difficult to model the entire process using experimental approaches in vitro. The ability to transfer DNA into non-metastatic mammary cells and to observe the induction of metastasis in vivo provides a means for identifying DNA sequences that are associated with the development of metastatic capability. Using these techniques, a metastasis-associated cytoskeletal calcium binding protein,
S100A4
(p9Ka), has been identified as an inducer of metastatic capability in benign rat mammary epithelial cells.
Metastasis
can also be induced in the rat mammary epithelial cells by fragments of DNA from metastatic, but not from benign, human breast tumour cells. These non-coding fragments of DNA act via the induction of osteopontin, an extracellular, integrin binding, calcium binding protein. Since both osteopontin and
S100A4
are thought to be associated with malignancy in human breast cancer specimens, gene transfer techniques can identify genes for metastasis-inducing proteins that may play a role in breast cancer, and further suggest that cell migration/motility might be important in the metastatic process.
...
PMID:Use of DNA transfer in the induction of metastasis in experimental mammary systems. 951 30
The murine 18A2/mts1 and its human homolog h-mts1 (
S100A4
), encoding a Ca2+-binding protein belonging to the S-100 family, are associated with high invasive and metastatic potentials of murine tumors, human tumor cell lines in vitro, and human tumors growing as xenografts. The nm23 is a putative metastasis-suppressor gene whose expression has been found to correlate inversely with the metastatic potential of some forms of human cancer. The products of both human genes alter cytoskeletal dynamics, with antagonistic effects. In view of the equivocal association of nm23 with the metastatic potential of human cancer, we suspected that the relative expression of h-mts1 and nm23 might reflect tumor progression more accurately than either of them alone. We describe here the expression of these genes in infiltrating ductal carcinomas of the breast and show that high h-mts1 expression is associated with metastatic spread to the regional lymph nodes. The expression of nm23 on its own did not show a statistically significant inverse correlation with nodal spread. However, the expression status of the two genes, taken together, correlated strongly with the occurrence of nodal
metastases
. Breast cancers with no detectable expression of h-mts1 were found to be estrogen and progesterone receptor positive. Expression of h-mts1 was not related to tumor differentiation. The clinical data, together with the state of expression of steroid receptors and the expression levels of h-mts1 and nm23 genes, were analyzed using artificial neural networks for accuracy in predicting nodal spread of the carcinomas. These analyses support the conclusion that, overall, h-mts1 expression appears to be associated with and indicative of more aggressive disease. Complemented with nm23, h-mts1 could provide a powerful marker of breast cancer prognosis.
...
PMID:Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression. 957 Jan 50
The rodent S100-related calcium-binding protein,
S100A4
induces metastasis in non-metastatic rat and mouse benign mammary cells and co-operates with benign-tumour-inducing changes in two transgenic mouse models, to yield metastatic mammary tumours. Co-transfection of the human gene for
S100A4
with pSV2neo into the benign rat mammary cell line, Rama 37, yielded cells which expressed a low level of the endogenous
S100A4
mRNA, and either high or undetectable levels of human
S100A4
mRNA. The cells which expressed a high level of human
S100A4
mRNA induced metastasis in the benign rat mammary cell line Rama 37 in an in vivo assay, whereas the cells which expressed an undetectable level of human
S100A4
did not induce any detectable
metastases
. The primary tumours arising from the
S100A4
-expressing cells contained high levels of immunocytochemically-detected
S100A4
and this high level of
S100A4
and the metastatic potential were maintained when cells from a metastasis were re-injected into syngeneic rats. The results show that the human
S100A4
possesses metastasis-inducing capabilities.
...
PMID:Human S100A4 (p9Ka) induces the metastatic phenotype upon benign tumour cells. 969 40
The
S100A4
gene (also known as pEL98/mts1/p9Ka/18A2/42A/calvasculin /FSP1/CAPL) encoding an S100-related calcium-binding protein is implied to be involved in the invasion and metastasis of murine tumor cells. In the present study, the expression of
S100A4
in human colorectal adenocarcinoma cell lines (SW837, LoVo, DLD-1, HT-29, SW480, SW620, WiDr, and Colo201) and surgically resected neoplastic tissues was examined to investigate whether
S100A4
plays a role in the invasion and metastasis of human tumor cells. Northern blot analysis using total RNA isolated from the adenocarcinoma cell lines revealed that five of the eight cell lines expressed substantial amounts of
S100A4
mRNA. Normal colon fibroblasts (CCD-18Co) expressed little of the RNA. Using surgically resected specimens, it seemed that the amount of
S100A4
mRNA in adenomas was nearly equal to that in normal colonic mucosa, whereas adenocarcinomas expressed a significantly higher amount of the RNA than did the adjacent normal colonic mucosa. Immunohistochemical analysis using formalin-fixed paraffin-embedded surgical specimens and monoclonal anti-
S100A4
antibody demonstrated that none of 12 adenoma specimens were immunopositive, whereas 8 of 18 (44%) focal carcinomas in carcinoma in adenoma specimens and 50 of 53 (94%) adenocarcinoma specimens were immunopositive. Interestingly, the incidence of immunopositive cells increased according to the depth of invasion, and nearly all of the carcinoma cells in 14
metastases
in the liver were positive. These results suggest that
S100A4
may be involved in the progression and the metastatic process of human colorectal neoplastic cells.
...
PMID:Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. 981 29
The DNA methylation status of the metastasis-associated
S100A4
gene in
S100A4
-positive and -negative human colon adenocarcinoma cell lines was examined. Northern and Western blot analyses revealed that HT-29, SW480, SW620, WiDr and Colo201 cells expressed
S100A4
, whereas SW837, LoVo and DLD-1 cells expressed little
S100A4
. Using CpG methylation-sensitive and -insensitive restriction enzymes and PCR-based methylation assay, it was found that the
S100A4
gene in HT-29, SW480, SW620, WiDr and Colo201 cells, but not in SW837, LoVo and DLD-1 cells, was hypomethylated and that the hypomethylation of the second intron was correlated well with the expression of
S100A4
. 5-Aza-2'-deoxycytidine, an inhibitor of the eukaryotic DNA methyltransferase, induced the expression of the
S100A4
gene in SW837, LoVo and DLD-1 cells, while it showed no effect on the expression of the gene in WiDr cells. These results indicate that hypomethylation of the
S100A4
gene results in the expression of the gene in colon adenocarcinoma cells.
Clin Exp
Metastasis
1998 Jul
PMID:Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines. 1009 42
The
S100A4
(mts1) is a gene associated with generation of
metastatic disease
. In order to analyze the consequences of alteration of the pattern of expression of the
S100A4
(mts1) gene we obtained strains of transgenic mice bearing the
S100A4
(mts1) gene under the control of a ubiquitous and constitutive 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) gene promoter. In transgenic animals the expression of the transgene RNA was detected in all organs, but only some of the organs showed elevated levels of the protein. Expression of the
S100A4
(Mts1) protein was downregulated in the organs that normally do not express the gene in the wild-type animal. The transgene RNA is detected in the polysomes indicating that it could be translated into the
S100A4
(Mts1) protein. The specificity of the
S100A4
(Mts1) protein expression is determined by a complex mechanism including regulation of translation and/or posttranslational degradation.
Invasion
Metastasis
PMID:Tissue-specific posttranscriptional downregulation of expression of the S100A4(mts1) gene in transgenic animals. 1036 89
S100A4
is a cell proliferation- and cancer metastasis-related gene. Previous studies have shown that over-expression of
S100A4
drives the cells into the S-phase of the cell cycle, with concomitant enhancement of p53 detection. This has led to the postulate that
S100A4
could be controlling cell cycle progression by sequestering p53 and abrogating its G1-S checkpoint control. Cells induced by
S100A4
to enter the S-phase do successfully negotiate the G2-M checkpoint control. Here we show that
S100A4
is also involved in the regulation of control at this checkpoint. Stathmin is known to be associated, together with p53 in controlling G2-M transition. We present evidence that the expression of
S100A4
and stathmin genes is up regulated in exponentially growing HeLa cells. They are down regulated in parallel when cell proliferation is inhibited by hyperthermia and 4-hydroxynonenal (4-HNE). We postulate that
S100A4
might directly induce stathmin up regulation to enable cells to enter into mitosis. Since wild-type p53 is known to down regulate stathmin expression, we further postulate this might also involve
S100A4
-mediated sequestration of p53. The expression of heme oxygenase (HO-1), a stress-response protein, has been used to monitor effects of hyperthermia, 12-O-tetradecanoly phorbol 13-acetate (TPA) and 4-HNE. All these treatments induced HO-1 and also when cells growing in serum-deficiency were restored with full serum. HO-1 induction occurred irrespective of
S100A4
expression status. HO-1 gene has responsive elements for many angiogenic agents and induces marked neovascularisation of tumours. We suggest therefore that
S100A4
may not possess angiogenic properties.
Clin Exp
Metastasis
1999
PMID:Stathmin is involved in S100A4-mediated regulation of cell cycle progression. 1108 85
1
2
3
4
5
6
7
8
Next >>